Sigyn Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Sigyn Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • Sigyn Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $3.02M, a 80.6% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $3.02M +$1.35M +80.6% Dec 31, 2023 10-K 2024-02-20
Q4 2022 $1.67M +$601K +56% Dec 31, 2022 10-K 2024-02-20
Q4 2021 $1.07M +$721K +204% Dec 31, 2021 10-K 2023-03-31
Q4 2020 $353K +$352K Dec 31, 2020 10-K 2022-03-21
Q4 2019 $434* -$3.45M Dec 31, 2019 10-K 2021-04-06
Q4 2018 $3.45M +$786K +29.5% Dec 31, 2018 10-K 2020-03-30
Q4 2017 $2.67M Dec 31, 2017 10-K 2019-04-01
Q4 2015 $1.32M +$1.07M +432% Dec 31, 2015 10-K 2016-03-30
Q4 2014 $248K Dec 31, 2014 10-K 2016-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.